Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27722750 | 0.88 | PARP1 (0.49) | PARP1MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL17030746 | 0.83 | CES2 (0.42) | PARP1CES2CES1BCHEALB | |
| SCHEMBL1259459 | 0.82 | ALB (0.57) | CES2CES1BCHEALBMAPT | |
| SCHEMBL31388520 | 0.82 | ALB (0.57) | CES2CES1BCHEALBMAPT | |
| SCHEMBL4446378 | 0.82 | CES2 (0.45) | CES2CES1BCHEALBMAPT | |
| SCHEMBL634076 | 0.81 | PARP1 (0.47) | PARP1MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL30554614 | 0.81 | PARP1 (0.47) | PARP1MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL937001 | 0.81 | ALDH1A1 (0.59) | CES2CES1BCHEALBMAPT | |
| SCHEMBL29789811 | 0.81 | ALDH1A1 (0.59) | CES2CES1BCHEALBMAPT | |
| Hydrochloric Acid SCHEMBL7069187 | 0.79 | PARP1 (0.46) | PARP1MAPTALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101006052-A | Pyrrole derivatives as pharmaceutical agents | EXELIXIS INC (US) | 2007-07-25 | — | — | CN | claimed |
| CN-106661035-B | The Pyrazolopyrimidine derivative of inhibitor as bruton's tyrosine kinase | 洛克索肿瘤学股份有限公司 | 2019-11-19 | — | — | CN | disclosed |
| CN-105985319-B | Aryl phthalazine compound and its preparation method and application | 复旦大学 | 2019-02-26 | — | — | CN | disclosed |
| CN-102781963-B | Functional modified NAv1.7 antibodies | UCB医药有限公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-102597002-B | The antibody of ion channel | UCB医药有限公司 | 2017-08-22 | — | — | CN | disclosed |
| CN-106661035-A | Pyrazolopyrimidine derivatives as inhibitors of bruton's tyrosine kinase | 莱德克斯制药公共有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-102573994-B | Novel bicyclic urea compounds | MERCK PATENT GMBH | 2015-06-24 | — | — | CN | disclosed |
| EP-2049478-B1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| CN-101511787-B | Substituted N-phenylmethyl-5-oxo-proline-2-amides as P2X 7-receptor antagonists and methods of their use | GLAXO GROUP LTD. (GB) | 2011-11-30 | — | — | CN | disclosed |
| US-8048907-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2011-11-01 | — | — | US | disclosed |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| CN-101511787-A | Substituted N-phenylmethyl-5-oxo-proline-2-amides as P2X 7-receptor antagonists and methods of their use | GLAXO GROUP LTD (GB) | 2009-08-19 | — | — | CN | disclosed |
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| EP-2049478-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | Glaxo Group Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008003697-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| CN-101006052-A | Pyrrole derivatives as pharmaceutical agents | EXELIXIS INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | PARP1 2650/4885CES2 3816/4885CES1 2950/4885 |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | PARP1 2650/4885CES2 3816/4885CES1 2950/4885 |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | P2RX1, P2RX3, P2RX7 | PARP1 2161/4885CES2 2986/4885CES1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.